Get the app
NSEHealthcare

Mankind Pharma Ltd (MANKIND)

NSE · Healthcare · Drug Manufacturers - Specialty & Generic

₹2,300.00+2.40%
Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue
₹4,031 cr
Revenue YoY
+12.9%
Net profit
₹568 cr
Profit YoY
+29.6%
EPS
₹13.74
EPS estimate
₹13.60
Net margin
14.1%

EPS came in at 13.74 against a street estimate of 13.60 — a beat of 1.0%.

Key statistics

Market cap
₹94,163 cr
P/E
46.1
Forward P/E
36.4
P/B
5.78
Book value
₹394.85
EPS (TTM)
₹49.48
52-week high
₹2,674.00
52-week low
₹1,909.70
50-day MA
₹2,445.64
200-day MA
₹2,278.97
Beta
0.45

Analyst view

with an average price target of ₹2,741.74.

Shareholding

Promoters
75.39%
Institutions
19.54%

Recent filings & reports

DocumentDate
Q1 FY27 earnings call
MANKIND PHARMA LIMITED – Q1 FY27 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Total Revenue: INR 4,031 crores, up 13% year-on-year (INR 3,570 crores in
2026-08-04
Investor presentation
MANKIND PHARMA LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Revenue from Operations: INR 4,031 Cr in Q1 FY27, up 12.9% YoY from INR 3,
2026-07-30
Annual report FY2026
MANKIND PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • 35th Annual General Meeting scheduled for Tuesday, August 4, 2026 at 3:30 P.M. (IST) vi
2026-07-09
Q4 FY26 earnings call
MANKIND PHARMA LIMITED – Q4 FY26 SUMMARY HEADLINE NUMBERS • Q4 FY26 revenue: INR 3,443 crores (11.8% YoY growth) vs INR 3,079 crores in Q4 FY25 • FY
2026-05-26
Quarterly results · Q4 FY26
MANKIND PHARMA LIMITED – DOCUMENT SUMMARY HEADLINE NUMBERS • Full Year FY2026 Revenue from Operations: ₹10,421.18 crores (vs ₹9,507.41 crores in FY2
2026-05-19
Investor presentation
MANKIND PHARMA LIMITED – Q4 & FY26 INVESTOR SUMMARY HEADLINE NUMBERS • FY26 Revenue: INR 14,278 Cr – 17.0% YoY growth (domestic INR 12,217 Cr up 14.
2026-05-19
Q3 FY26 earnings call
MANKIND PHARMA LIMITED – Q3 & 9M FY26 EARNINGS CALL SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 3,567 crores, up 11.5% YoY (Q3 FY25: INR 3,199 c
2026-02-09
Quarterly results · Q3 FY26
MANKIND PHARMA LIMITED – Q3 FY26 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q3 FY26 Revenue: INR 3,567 Crore, up 11.5% YoY • Q3 FY26 Adjusted EBIT
2026-02-03

Readable in the app.

Deals & corporate news

AnnouncementDate
Acquisition of another business or entity announced
Mankind Pharma Limited has incorporated a wholly owned subsidiary company in the Netherlands named 'Mankind Pharma (Netherlands) B.V.' on August 13, 2026. This was a previously disclosed pla
2026-08-13
Final update on stake sale of Broadway Hospitality Services
Final update on Stake Sale of Broadway Hospitality Services Private Limited
2026-07-27
Acquisition of another business announced
Mankind Pharma Limited has informed the Exchange about Acquisition
2026-07-11
Acquisition announcement by pharmaceutical company
Mankind Pharma Limited has informed the Exchange about Acquisition
2026-06-02
Acquisition announced by Mankind Pharma Limited
Mankind Pharma Limited has informed the Exchange about Acquisition
2026-05-19

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Mankind Pharma Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Data updated 2026-09-18.